Connect your AI

Kura Oncology KURA Prepaid & Other Current

Prepaid & Other Current at other companies

Johnson & JohnsonJNJ

$4.82B+17.8%

AmgenAMGN

$4.11B+26.2%

ExelixisEXEL

$75.88M+29.3%

Syndax PharmaceuticalsSNDX

$16.1M+90.3%

AbbVieABBV

$150M-97.3%

Corvus PharmaceuticalsCRVS

$3.19M+166%

Other financials

Income statement

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kura Oncology's prepaid & other current?: Kura Oncology (KURA) reported prepaid & other current of $32.77M in Q1 2026.
How has Kura Oncology's prepaid & other current changed year-over-year?: Kura Oncology's prepaid & other current increased by 89.8% year-over-year, from $17.26M to $32.77M.
What is the long-term trend for Kura Oncology's prepaid & other current?: Over 5 years (2020 to 2025), Kura Oncology's prepaid & other current has grown at a 52.0% compound annual growth rate (CAGR), from $3.97M to $32.21M.
What does prepaid & other current mean?: Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.